Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00063817|
Recruitment Status : Completed
First Posted : July 8, 2003
Last Update Posted : December 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|End-stage Renal Disease Renal Transplantation Kidney Transplantation||Drug: Conditioning Regimen||Phase 1|
Of the two currently available treatments for kidney failure, long-term dialysis and kidney transplantation, only kidney transplantation provides a potential cure. After a kidney transplant, the body's immune system recognizes the kidney as foreign and tries to attack and destroy it in a process called rejection. To avoid rejection, participants must take medications called immunosuppressants or anti-rejection drugs. It is believed that by transplanting bone marrow at the same time as a solid organ such as a kidney, a state of "mixed chimerism" (a mixing of the donor and recipient's immune system) can be achieved. Mixed chimerism may prevent rejection without the need for anti-rejection drugs.
Participants in this study will receive a simultaneous bone marrow and kidney transplant from the same living related donor in an attempt to establish mixed chimerism. Prior to transplantation, participants will undergo a "conditioning regimen" involving cyclophosphamide chemotherapy, radiation to the thymus gland, and four immunosuppressive medications: cyclosporine A, a man-made antibody known as rituximab to suppress B cells, a short course of steroids, and a T-cell depleting antibody known as MEDI-507. MEDI-507 is an investigational medication that has not been approved by the FDA. The primary goal of the study is to investigate the safety of the conditioning regimen and its ability to promote mixed chimerism so that the transplanted kidney is not destroyed. The study will also determine whether participants with mixed chimerism can eventually be safely removed from long-term immunosuppressive therapy following transplantation.
Participants will be assessed before and after transplantation and will be followed ≤36 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)|
|Study Start Date :||June 2003|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||July 2009|
Experimental: Conditioning Regimen
Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.
Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Drug: Conditioning Regimen
Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Other Name: nonmyeloablative preparative regimen
- Graft Survival Twenty-Four Months Post Transplantation [ Time Frame: 24 months (2 Years) Post Transplantation ]Defined by kidney transplant survival at month 24 post transplantation with successful withdrawal of cyclosporine following transplantation, in the absence of maintenance immunosuppression.
- Participant Survival [ Time Frame: Up to thirty-six months (3 Years) Post Transplantation ]During the three-year post-transplant follow-up period for enrolled participants.
- Graft Survival [ Time Frame: Up to thirty-six months (3 Years) Post Transplantation ]During the three-year post-transplant follow-up period for enrolled participants.
- Change from Baseline in Renal Function Using Serum Creatinine [ Time Frame: Up to thirty-six months (3 Years) Post Transplantation ]Changes in serum creatinine levels from baseline through post transplantation follow-up period.
- Number of Episodes of Acute or Chronic Graft Versus Host Disease (GVHD) [ Time Frame: From Week 1 through thirty-six months (3 Years) Post Transplantation ]Evaluations for suspected GVHD, including biopsies as appropriate, during routine and/or for cause assessments.
- Number of Adverse Events [ Time Frame: Participant enrollment through <=thirty-six months (3 Years) Post Transplantation ]As defined by protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00063817
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||David H. Sachs, MD||Department of Medicine, Massachusetts General Hospital|
|Principal Investigator:||A. Benedict Cosimi, MD||Department of Medicine, Massachusetts General Hospital|